Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Tekijä Schernthaner, G, Matthews, DR, Charbonnel, B, Hanefeld, M, Brunetti, P

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Tekijä Hanefeld, M, Brunetti, P, Schernthaner, G, Matthews, DR, Charbonnel, B

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Tekijä Charbonnel, B, Matthews, DR, Schernthaner, G, Hanefeld, M, Brunetti, P

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study... Tekijä Matthews, DR, Charbonnel, B, Hanefeld, M, Brunetti, P, Schernthaner, G

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Tekijä Charbonnel, B, Schernthaner, G, Brunetti, P, Matthews, DR, Urquhart, R, Tan, M, Hanefeld, M

Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site Tekijä Hadzijusufovic, E, Albrecht-Schgoer, K, Huber, K, Hoermann, G, Grebien, F, Eisenwort, G, Schgoer, W, Herndlhofer, S, Kaun, C, Theurl, M, Sperr, W, Rix, U, Sadovnik, I, Jilma, B, Schernthaner, G, Wojta, J, Wolf, D, Superti-Furga, G, Kirchmair, R, Valent, P